High Tower Advisors, LLC Salarius Pharmaceuticals, Inc. Transaction History

High Tower Advisors, LLC

  • $61.2 Billion
  • Q1 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022
BUY
$0.16 - $0.42 $4,248 - $11,152
26,553 New
26,553 $6,000
Q1 2022

May 12, 2022
SELL
$0.34 - $0.54 $12,240 - $19,440
-36,000 Closed
0 $0
Q4 2021

Feb 10, 2022
BUY
$0.49 - $1.01 $4,900 - $10,100
10,000 Added 38.46%
36,000 $18,000
Q3 2021

Nov 12, 2021
BUY
$0.8 - $1.15 $20,800 - $29,899
26,000 New
26,000 $26,000

About Salarius Pharmaceuticals, Inc.

SLRX Quotes by TradingView
  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $5.43M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email